Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer : a Multicentre, Single Arm, Phase 2 Trial

NCT07104149 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

NCT NCT07104149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer : a Multicentre, Single Arm, Phase 2 Trial
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Recruiting
Start date
March 10, 2025
Completion date
June 30, 2027
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ecog score of 0-1, expected survival time >6 months, female, age ≥ 18 years old, histologically confirmed cervical cancer, figo stage ib3, iia2, iib, iiic, and assessed by the researcher as resectable lesion, locally advanced cervical cancer, no previous systemic treatment for the current disease, including surgery, antitumor radiochemotherapy/immunotherapy, subjects should take contraceptive measures, sufficient organ function, the result of the urine or serum pregnancy test for the subject is negative